patients will be excluded if any of the following conditions apply: known sensitivity/allergy to tcz or other monoclonal antibodies ast/alt>5 times unl, platelet counts <50,000 or neutrophil counts <500 active tb pregnant receipt of mechanical ventilation has received other immunomodulatory drugs (including tcz) in the past for the treatment of other conditions individuals, in the opinion of the investigator, where progression to death is imminent and inevitable in the next 24 hours irrespective of treatment provision or who have signed a dnr. participating in other clinical trials (subject to approval) any serious medical condition or abnormal clinical laboratory tests which in the judgement of the investigator may compromise patient safety should he/she participate in the study.

patients will be excluded if any of the following conditions apply: known sensitivity/allergy to tcz or other monoclonal antibodies ast/alt>5 times unl, platelet counts <50,000 or neutrophil counts <500 active tb pregnant receipt of mechanical ventilation has received other immunomodulatory drugs (including tcz) in the past for the treatment of other conditions individuals, in the opinion of the investigator, where progression to death is imminent and inevitable in the next 24 hours irrespective of treatment provision or who have signed a dnr. participating in other clinical trials (subject to approval) any serious medical condition or abnormal clinical laboratory tests which in the judgement of the investigator may compromise patient safety should he/she participate in the study.

patients will be excluded if any of the following conditions apply: 1. known sensitivity/allergy to tcz or other monoclonal antibodies 2. ast/alt>5 times unl, platelet counts <50,000 or neutrophil counts <500 3. active tb 4. pregnant 5. receipt of mechanical ventilation 6. has received other immunomodulatory drugs (including tcz) in the past for the treatment of other conditions 7. individuals, in the opinion of the investigator, where progression to death is imminent and inevitable in the next 24 hours irrespective of treatment provision or who have signed a dnr. 8. participating in other clinical trials (subject to approval) 9. any serious medical condition or abnormal clinical laboratory tests which in the judgement of the investigator may compromise patient safety should he/she participate in the study.

patients will be excluded if any of the following conditions apply: 1. known sensitivity/allergy to tcz or other monoclonal antibodies 2. ast/alt>5 times unl, platelet counts <50,000 or neutrophil counts <500 3. active tb 4. pregnant 5. receipt of mechanical ventilation 6. has received other immunomodulatory drugs (including tcz) in the past for the treatment of other conditions 7. individuals, in the opinion of the investigator, where progression to death is imminent and inevitable in the next 24 hours irrespective of treatment provision or who have signed a dnr. 8. participating in other clinical trials (subject to approval) 9. any serious medical condition or abnormal clinical laboratory tests which in the judgement of the investigator may compromise patient safety should he/she participate in the study.